贝卡林作为治疗系统性硬化症的潜在候选者.
Giada Cimino1, Federica Rapisarda2, Rossella Talotta3
1Nursing Degree School, University of Messina, Messina, Italy.
Inflammopharmacology
|June 23, 2025
概括
拜卡林是一种天然化合物,通过解决其核心问题:免疫功能障碍,血管病变和纤维化,显示出治疗系统性硬化症 (SSc) 的潜力. 需要进一步的临床研究来证实它在SSc患者中的有效性和安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性硬化症 (SSc) 是一种复杂的结缔组织疾病,涉及免疫细胞激活,内皮功能障碍和纤维化.
- 目前的SSc治疗是有限的,因为不完全理解病原体.
- 贝卡林是来自Scutellaria baicalensis的黄类化合物,在各种临床前疾病模型中已经证明了它的有效性.
研究的目的:
- 审查贝卡林在管理SSc.中的潜力.
- 探索贝卡林对SSc关键病理特征的机制:血管病变,免疫功能障碍和纤维化.
主要方法:
- 现有文献的叙述性审查.
- 对贝卡林已知药理作用的分析.
- 对SSc病原性相关性的评估.
主要成果:
- 拜卡林表现出多种机制,包括TLR4对抗性,TGF-β/Smad3通路抑制和抗氧化作用.
- 这些特性与抵消SSc的致病性三元组相一致.
- 临床前数据表明,在相关条件下,有潜在的益处.
结论:
- 贝卡林基于其多方面的药理学特征,为SSc提供了一个有前途的治疗候选药物.
- 它在治疗血管病变,免疫功能障碍和纤维化方面的潜力需要进一步研究.
- 临床试验对于确定贝卡林在SSc患者中的有效性和安全性至关重要.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240